February 17, 2005
EntreMed Appoints Pharmaceutical Executive to Senior Management TeamFebruary 14, 2005
EntreMed Reports on Anticancer Progress at Angiogenesis SymposiumJanuary 19, 2005
Report Demonstrates Activity of 2ME2 With Paclitaxel in Head and Neck CarcinomaJanuary 05, 2005
EntreMed Commences Clinical Trials of Panzem(R) NCD in Patients With Advanced CancerCASI Pharmaceuticals, Inc. is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products. CASI has built a portfolio that includes approved and investigational assets. We conduct our commercial, clinical operations and R&D activities through our subsidiaries in China and branch office in Rockville, Maryland.
EVOMELA® (melphalan) for Injection is proprietary to Acrotech Biopharma LLC and its affiliates.
© 2022 CASI Pharmaceuticals Inc.
All Rights Reserved.